NewAmsterdam Pharma Company N.V. $NAMS is Decheng Capital LLC’s 5th Largest Position

Decheng Capital LLC trimmed its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 14.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 657,051 shares of the company’s stock after selling 112,949 shares during the quarter. NewAmsterdam Pharma makes up approximately 3.3% of Decheng Capital LLC’s portfolio, making the stock its 5th largest position. Decheng Capital LLC owned approximately 0.58% of NewAmsterdam Pharma worth $18,687,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in NAMS. Mather Group LLC. acquired a new stake in shares of NewAmsterdam Pharma during the third quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in NewAmsterdam Pharma in the 3rd quarter worth approximately $30,000. Wolverine Asset Management LLC purchased a new position in NewAmsterdam Pharma during the 3rd quarter worth approximately $69,000. The Manufacturers Life Insurance Company grew its position in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after purchasing an additional 544 shares in the last quarter. Finally, Letko Brosseau & Associates Inc. acquired a new stake in NewAmsterdam Pharma during the 2nd quarter valued at $213,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Down 4.0%

Shares of NASDAQ:NAMS opened at $28.62 on Monday. The firm has a fifty day moving average of $33.10 and a two-hundred day moving average of $33.47. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00. The firm has a market capitalization of $3.29 billion, a P/E ratio of -16.54 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.92 million. Equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Wall Street Zen lowered NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Leerink Partners restated an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Finally, Guggenheim lifted their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average price target of $47.10.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $30.30, for a total value of $3,165,350.10. Following the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at $2,099,850.60. This represents a 60.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of NewAmsterdam Pharma stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the sale, the chief executive officer owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This represents a 71.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 1,466,933 shares of company stock valued at $48,448,017. 20.84% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.